Scroll Down Arrow

GCP for Clinical Investigations of Devices

This course provides training for research personnel involved in clinical investigations of devices.


About this Course


The GCP Device Basic course is intended for research personnel involved in investigations of devices. It includes FDA regulations and guidance as well as International Organization for Standardization Guidelines ISO 14155:2011.

It also provides an overview of investigator obligations in conducting clinical investigations of devices, as well as managing investigational devices according to GCP requirements, monitoring, audits and inspections, and informed consent for clinical investigations.

Language Availability: English, Korean, Portuguese, Spanish

Suggested Audiences: Research Staff who are Involved in the Design and Conduct of Clinical Trials with Devices, Research Staff who are Involved in the Oversight or Management of Clinical Trials with Devices, Research Teams, Clinical Research Coordinators, Clinical Research Organizations (CROs), Investigators, Key Study Personnel, Research Nurses, Research Staff, Sponsors

Organizational Subscription Price: Included in organizational subscription
Independent Learner Price: $110 per person


CE Credits and Units


To purchase CE credits and units, you need to be affiliated with an organization that subscribes to this course or buy it as an independent learner first.

Physicians

AMA PRA Category 1 Credit

3 Credits
(6 CE certified modules)
$50

1 March 2016
30 April 2019

Psychologists

CE Credit/Hour

3 Credits
(6 CE certified modules)
$50

1 March 2016
30 April 2019

Other Participants

Certificate of Participation

3 Credits
(6 CE certified modules)
$40

1 March 2016
30 April 2019


Course Content


Toggle Content The CITI Good Clinical Practice Course for Clinical Investigations of Devices

Provides an introduction to the course and a link to the Belmont Report. The Belmont Report is required reading for all CITI Program participants as it provides the ethical framework for the federal regulations designed to protect human research subjects.

Recommended Use: Required
ID (Language): 14633 (English), 15286 (Spanish), 16349 (Portuguese), 16042 (Korean)

Toggle Content Overview of U.S. FDA Regulations for Investigational Devices CME/CEU Badge

Reviews the responsibilities of investigators conducting clinical research involving medical devices. Discusses the differences between significant risk (SR) and non-significant risk (NSR) devices. Reviews the characteristics and marketing requirements for Class I, II, and III devices. Provides an overview of investigator and institutional review board/independent ethics committee (IRB/IEC) responsibilities associated with clinical trials of medical devices and a discussion of the different options associated with early access to investigational devices in advance of FDA approval.

Recommended Use: Required
ID (Language): 14637 (English), 15290 (Spanish), 16353 (Portuguese), 16046 (Korean)
Author(s): Daniel Redline, BA - Gilead Sciences

Toggle Content Investigator Obligations in FDA-Regulated Clinical Investigations of Devices CME/CEU Badge

Describes the commitments and obligations assumed by investigators when conducting clinical investigations of devices, including investigator agreement, financial disclosures, and IRB submission and approval of research. Identifies required study records and reporting requirements. Reviews the investigator's relationship with the sponsor organization as well as the investigator's commitment to the subjects, the institutional review board/independent ethics committee (IRB/IEC), the International Organization for Standardization (ISO), and the FDA.

Recommended Use: Required
ID (Language): 14635 (English), 15288 (Spanish), 16351 (Portuguese), 16044 (Korean)
Author(s): Daniel Redline, BA - Gilead Sciences

Toggle Content Conducting Investigator-Initiated Clinical Investigations of Devices CME/CEU Badge

Highlights the requirements for conducting investigator-initiated trials of devices (investigator-initiated device studies). Describes the role of the sponsor-investigator. Discusses significant risk (SR) and non-significant risk (NSR) device studies, sponsor-investigator investigational device exemptions (IDEs), and reporting requirements.

Recommended Use: Required
ID (Language): 14634 (English), 15287 (Spanish), 16350 (Portuguese), 16043 (Korean)
Author(s): Daniel Redline, BA - Gilead Sciences

Toggle Content Managing Investigational Devices According to GCP Requirements CME/CEU Badge

Focuses on specific requirements associated with the management of investigational products by principal investigators, with a specific focus on GCP standards and ISO 14155. Discusses requirements for investigational devices, including sponsor requirements for selecting investigators, investigator control of devices, packaging and shipping, and storage of devices.

Recommended Use: Required
ID (Language): 14636 (English), 15289 (Spanish), 16352 (Portuguese), 16045 (Korean)
Author(s): Daniel Redline, BA - Gilead Sciences

Toggle Content Informed Consent in Clinical Investigations of Devices CME/CEU Badge

Provides an overview of the informed consent guidelines, the required and optional elements of informed consent and the process for obtaining informed consent. Identifies challenges associated with informed consent and the concept of vulnerable subjects. Describes the exceptions to the requirement for obtaining informed consent under FDA regulations and ISO 14155.

Recommended Use: Required
ID (Language): 14638 (English), 15291 (Spanish), 16354 (Portuguese), 16047 (Korean)
Author(s): Diane Paul, MS, RN - Drug Development Associates, LLC

Toggle Content Monitoring Clinical Investigations of Devices CME/CEU Badge

Describes the obligation of industry research sponsors to monitor the progress of clinical trials under an investigational device exemption (IDE) in the U.S. Describes types of site visits conducted by industry sponsors along with the basic requirements for each type of site visit. Reviews the role of the investigative site during interactions with industry sponsors as well as the required documentation and record keeping in studies regulated by the FDA.

Recommended Use: Required
ID (Language): 14639 (English), 15292 (Spanish), 16355 (Portuguese), 16048 (Korean)
Author(s): Daniel Redline, BA - Gilead Sciences

Toggle Content Audits and Inspections of Clinical Investigations of Devices CME/CEU Badge

Summarizes monitoring, audits, and inspections of clinical trials conducted according to standards for GCP. Describes the different entities that can inspect or audit a clinical trial, the factors that can determine whether an investigator will be audited, what the auditors and inspectors are looking for, and the results and consequences that can stem from FDA inspection findings. Because some FDA-regulated research may involve federal funds there may also be Office for Human Research Protections (OHRP) oversight. As a result, it includes an overview of OHRP compliance site visits and outcomes. The purpose of the FDA Bioresearch Monitoring Program is also discussed.

Recommended Use: Required
ID (Language): 14640 (English), 15293 (Spanish), 16356 (Portuguese), 16049 (Korean)
Author(s): Daniel Redline, BA - Gilead Sciences

Toggle Content Reporting Requirements for Clinical Investigations of Devices CME/CEU Badge

Explains the reporting requirements of 21 CFR 812, the FDA regulations for the conduct of investigational device studies and ISO 14155. Defines the various categories of events that must be reported for U.S. and international studies. Describes the steps sponsors must take to determine whether or not an event or an aggregate of events must be reported to the FDA or other regulatory authorities.

Recommended Use: Required
ID (Language): 14641 (English), 15294 (Spanish), 16357 (Portuguese), 16050 (Korean)
Author(s): Daniel Redline, BA - Gilead Sciences

Toggle Content Completing the CITI Program’s GCP Course for Clinical Investigations of Devices

Provides learners with instructions on how to review completed modules, download or print their completion report, or complete a form to order CME or CEU credits. Also provides links to federal regulations, general device information, and other resources including Council for International Organizations of Medical Sciences (CIOMS), International Council for Harmonisation (ICH) Good Clinical Practices (E6), MedWatch (Safety Information and Adverse Event Reporting), and National Institutes of Health (NIH).

Recommended Use: Required
ID (Language): 14642 (English), 15295 (Spanish), 16358 (Portuguese), 16051 (Korean)


Additional Modules of Interest


Toggle Content Humanitarian Use Devices (HUDs)

Provides a basic overview of the U.S. Food and Drug (FDA) regulations and responsibilities regarding HUDs. It describes the HUD program and Humanitarian Device Exemption (HDE) regulatory process, and explains the applicable requirements and differences between 1) a “clinical use” of a HUD to treat or diagnose patients or 2) a “HUD investigation.” It also categorizes the FDA regulations and IRB review requirements for HUD investigations within and outside of the HDE approved indications, and identifies additional federal rules or institutional requirements that may apply to the clinical use of a HUD or HUD investigations.

Recommended Use: Supplemental
ID (Language): 16306 (English)
Author(s): Belinda Smith, MS, RD, CCRC - University of Kentucky; Kevin L. Nellis, MS, CIP - Maimonides Medical Center; Ada Sue Selwitz, MA - University of Kentucky

Toggle Content Overview of the Clinical Trial Agreement (CTA)

Discusses the general purpose of a CTA, roles and responsibilities of parties to the CTA, and how the CTA fits into the research enterprise. It also compares and contrasts clinical trials involving drugs, biologics, and devices from a CTA perspective.

Recommended Use: Supplemental
ID (Language): 17356 (English)
Author(s): Dex Bilkic, HBSc, MBA - Boehringer-Ingelheim; JoAnn Pfeiffer, DrSC, RAC, CCRA - Arizona State University

Toggle Content Understanding the Terms of the Clinical Trial Agreement (CTA)

Provides an overview of the context behind certain CTA terms and sections, types of language used for CTA sections, and some key elements of each section. It also outlines what should be addressed in the key sections of the CTA and the aim for each section.

Recommended Use: Supplemental
ID (Language): 17357 (English)
Author(s): Dex Bilkic, HBSc, MBA - Boehringer-Ingelheim; JoAnn Pfeiffer, DrSC, RAC, CCRA - Arizona State University

Toggle Content Role of the Researcher and Site in Managing the Clinical Trial Agreement (CTA)

Discusses key roles of the researcher and site in managing the CTA, including initial assessment, review, and implementation. It also describes how the CTA is linked to site policies, the protocol, and the informed consent form, and identifies key sections of the CTA that could present risk to the site.

Recommended Use: Supplemental
ID (Language): 17358 (English)
Author(s): Dex Bilkic, HBSc, MBA - Boehringer-Ingelheim; JoAnn Pfeiffer, DrSC, RAC, CCRA - Arizona State University

Toggle Content Clinical Trial Agreement (CTA) Negotiation for Researchers and Sites

Addresses strategies and preparation for CTA and study budget negotiations. It also identifies terminology and alternative wording options to ensure a fair and balanced CTA.

Recommended Use: Supplemental
ID (Language): 17359 (English)
Author(s): Dex Bilkic, HBSc, MBA - Boehringer-Ingelheim; JoAnn Pfeiffer, DrSC, RAC, CCRA - Arizona State University